Drug Profile
MP 106 - Mycoplus
Latest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Mycoplus
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for clinical-Phase-Unknown development in Methicillin-resistant-Staphylococcus-aureus-infections in South Korea
- 07 Jul 2016 Clinical trials in Methicillin-resistant Staphylococcus aureus infections in South Korea (unspecified route) prior to July 2016